UNIGE document Scientific Article
previous document  unige:145652  next document
add to browser collection

Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1

CollaborationWith : Calmy, Alexandra
Published in New England Journal of Medicine. 2019, vol. 381, no. 9, p. 816-826
Abstract An efavirenz-based regimen (with a 600-mg dose of efavirenz, known as EFV600) was the World Health Organization preferred first-line treatment for human immunodeficiency virus type 1 (HIV-1) infection until June 2018. Given concerns about side effects, dolutegravir-based and low-dose efavirenz-based combinations have been considered as first-line treatments for HIV-1 in resource-limited settings.
Keywords AdultBenzoxazines/administration & dosage/adverse effectsDrug Therapy, CombinationFemaleHIV Infections/drug therapyHIV Integrase Inhibitors/adverse effects/therapeutic useHIV-1/genetics/isolation & purificationHeterocyclic Compounds, 3-Ring/administration & dosage/adverse effectsHumansLamivudine/administration & dosageMaleObesity/chemically inducedPregnancyRNA, Viral/bloodTenofovir/administration & dosageViral Load/drug effectsWeight Gain/drug effects
PMID: 31339676
Full text
Article (Published version) (377 Kb) - public document Free access
Research group VIH/SIDA (930)
Project ANRS 12313
(ISO format)
NAMSAL ANRS 12313 STUDY GROUP. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. In: New England Journal of Medicine, 2019, vol. 381, n° 9, p. 816-826. doi: 10.1056/NEJMoa1904340 https://archive-ouverte.unige.ch/unige:145652

62 hits



Deposited on : 2020-12-01

Export document
Format :
Citation style :